Company intelligence / Profile preview

Conscience21

Ownership: Private
Development stage: Other

Overview

Conscience uses AI and open science to advance drug discovery, focusing on collaborative challenges to identify new molecules for targets such as CBLB in cancer. The organization brings together researchers, industry, funders, and patients through open challenges and investments in promising drug discovery projects. No clinical results are reported; activities are at the computational prediction/early validation stage.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

Collaborates with industry, academia, non-profits through open science initiatives

Beyond the preview

Go deeper on Conscience21.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Conscience21.

Explore the full profile